Since founding Carterra (formerly Wasatch Microfluidics) in 2005, Mr. Eckman has been instrumental in securing funding, attracting key employees and advisors, developing strategic partnerships, designing Carterra’s proprietary flexible manufacturing process, securing international distributorships, and building out the sales channels for current products. Mr. Eckman previously worked with the Lassonde New Venture Development Center, moving university technologies into the marketplace. Mr. Eckman graduated summa cum laude in Business Administration and Asian Studies from the University of Utah. At graduation, he was awarded the Outstanding Scholar in Business Administration and the Honors Baccalaureate Award. Mr. Eckman also received a M.S. in Mechanical Engineering (microfluidics focus) from the University of Utah.
Dr. Keegan has more than 30 years of experience in life science businesses. Most recently as CEO at ForteBio, Inc. he led the Series C financing which raised $25M, established product development and sales strategies that resulted in 2007-11 compounded annual revenue growth of 45% to $27M. During his 9 year tenure as CEO at Molecular Devices Corporation, he grew the company’s revenues from $30M to $185M through internal growth and acquisitions. In early 2007, he oversaw its acquisition by MDS Corporation for $615M. He currently serves on the Board of Directors of Arrayjet LTD, Bio-Techne (NASDAQ:TECH), Halo Labs, Interpace Diagnostics (NASDAQ:IDXG), Labcyte as Chairman and Nanomedical Diagnostics as Executive Chairman. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.
Jack Ball is CEO and a board member at Solulink, a San Diego biotech tools company supplying HybriLink™ technology that enables user attachment of fluorophores to antibodies in 30 minutes with no purification. This technology is highly suited to the multicolor flow cytometry market. He is President, Tyball Associates, LLC, a consulting company bringing 21st century sales and marketing strategies that are highly capital efficient, to companies in the biotech tools space. He is an Adjunct Professor at the University of Michigan, Ross Business School in Entrepreneurial Studies. In addition, he serves on the board of directors of the following eight companies: Aquaro Biosystems where he is Executive Chairman, Celsee Diagnostics, DNA Software, ENT Biotech Solutions, NanoCellect, Swift Bioscience and Wasatch Microfluidics. He sold ViroCyt and IntelliCyt in mid-2016 for $16M and $90M respectively as a former board member
Mr. Ball has a long and proven record for bringing life science products to market and capitalizing on existing product potential. Most recently he was Chief Commercial Officer at Accuri Cytometers where he developed a novel commercialization model that was highly capital efficient. He and the management team sold the company to Becton Dickinson for $205M in March 2011. Prior to Accuri Cytometers, he was CEO of Amnis Corporation, a venture backed technology start-up developing and selling high-end imaging flow cytometers. He has also served as Chief Commercial Officer for Molecular Probes, Inc., the world leader in reagents for cell analysis, including flow cytometry consumables. Prior to that he was with Orchid Biosciences as Sr. VP and General Manager and with Amersham Pharmacia Biotech Inc., where he rose to President, Region North America and was responsible for sales, marketing, and customer support for all products sold in North America.
John Lillig has over 40 years’ experience in the management & guidance of clinical diagnostics & life science businesses and operations. As well as serving as a Director on Wasatch Microfluidics’ Board of Directors, he is currently the Executive Chairman of DYNEX Technologies and Agena Bioscience, serves on the Board of Directors of MANTA Instruments and COMPAS Software, and is CEO of IRORI Technologies. Before Agena, John served as Senior VP and Managing Director of the Brooks Life Science Systems Division of Brooks Automation. Prior to Brooks, John was the Founder, Chairman, President, CEO of Nexus Biosystems. Before founding Nexus, John served as CTO for Discovery Partners International (DPI) and VP/GM of DPI’s Systems Division. Prior to DPI he served as Division Manager of the Analytical Systems Division of Bio-Rad Laboratories. Earlier in his career, John held several key management positions during his 19 years at Beckman Instruments’ Clinical Diagnostics & Life Science operations. John has 15 patents and received his B.S. in engineering from California Polytechnic University.
Alex is a Partner of the Telegraph Hill Partners (THP) venture capital firm. Prior to joining THP, Alex worked in Business Development in the Oncology/Multiple Sclerosis Group at Genzyme Corporation. At Genzyme, he structured licensing and M&A transactions in the biotechnology and pharmaceuticals space. He has also worked as a Portfolio Manager at BlueMountain Capital Management and as an Analyst in Investment Banking at Bank of America Securities. Alex represents THP on the boards of Argonaut, Carterra and Dynex. He is a board observer at Agena Bioscience. Alex holds an MBA with honors from Northwestern University’s Kellogg School of Management and a Bachelor of Science in Economics from Duke University.